fidaxomicin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
aminoglycosides, antibiotics obtained from various Micromonospora 4180 873857-62-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lipiarmicin
  • lipiarmycin
  • tiacumicin B
  • dificid
  • fidaxomicin
  • dificlir
Fidaxomicin is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum. In vitro, fidaxomicin is active primarily against species of clostridia, including Clostridium difficile by inhibiting RNA synthesis by RNA polymerases.
  • Molecular weight: 1058.05
  • Formula: C52H74Cl2O18
  • CLOGP: 7.19
  • LIPINSKI: 4
  • HAC: 18
  • HDO: 7
  • TPSA: 266.66
  • ALOGS: -4.93
  • ROTB: 15

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
May 27, 2011 FDA CUBIST PHARMS
July 2, 2018 PMDA Astellas Pharma Inc

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Clostridium difficile infection 193.23 36.67 54 1162 29868 63457938
Disease recurrence 133.62 36.67 40 1176 27990 63459816
Clostridium difficile colitis 63.07 36.67 21 1195 20548 63467258
Clostridium test positive 62.17 36.67 14 1202 3187 63484619
Avian influenza 61.35 36.67 8 1208 64 63487742
Drug ineffective 58.26 36.67 84 1132 1044681 62443125
Pseudomembranous colitis 57.13 36.67 13 1203 3099 63484707
Renal graft infection 51.03 36.67 8 1208 254 63487552
Urinary tract infection pseudomonal 41.59 36.67 8 1208 845 63486961
Diarrhoea 40.22 36.67 58 1158 715308 62772498
Treatment failure 38.09 36.67 31 1185 199012 63288794

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Clostridium difficile infection 81.05 49.98 25 662 18873 34937371
Diarrhoea 58.71 49.98 53 634 389859 34566385
Drug ineffective 55.28 49.98 55 632 456696 34499548

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Clostridium difficile infection 211.03 33.15 64 1617 42621 79700086
Disease recurrence 93.26 33.15 35 1646 44074 79698633
Drug ineffective 89.93 33.15 111 1570 1080802 78661905
Clostridium difficile colitis 80.73 33.15 29 1652 32254 79710453
Diarrhoea 68.99 33.15 88 1593 880401 78862306
Pseudomembranous colitis 68.39 33.15 17 1664 5357 79737350
Avian influenza 58.36 33.15 8 1673 87 79742620
Clostridium test positive 55.74 33.15 15 1666 6439 79736268
Treatment failure 53.20 33.15 37 1644 170449 79572258
Renal graft infection 44.32 33.15 8 1673 542 79742165
Septic shock 41.45 33.15 28 1653 122773 79619934
Urinary tract infection pseudomonal 34.87 33.15 8 1673 1790 79740917

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A07AA12 ALIMENTARY TRACT AND METABOLISM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
INTESTINAL ANTIINFECTIVES
Antibiotics
FDA CS M0028311 Macrolides
FDA EPC N0000175431 Macrolide Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:37416 RNA polymerase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Clostridium difficile infection indication 186431008
Pseudomembranous enterocolitis indication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.95 acidic
pKa2 9.53 acidic
pKa3 11.96 acidic
pKa4 12.76 acidic
pKa5 13.32 acidic
pKa6 13.74 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
200MG DIFICID CUBIST PHARMS LLC N201699 May 27, 2011 RX TABLET ORAL 7906489 March 4, 2027 TREATMENT OF CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN PATIENTS FROM 6 MONTHS OF AGE AND OLDER
200MG DIFICID CUBIST PHARMS LLC N201699 May 27, 2011 RX TABLET ORAL 7906489 March 4, 2027 TREATMENT OF MICROBIAL INFECTIONS
40MG/ML DIFICID CUBIST PHARMS LLC N213138 Jan. 24, 2020 RX FOR SUSPENSION ORAL 7906489 March 4, 2027 TREATMENT OF CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN PATIENTS FROM 6 MONTHS OF AGE AND OLDER
200MG DIFICID CUBIST PHARMS LLC N201699 May 27, 2011 RX TABLET ORAL 8859510 July 31, 2027 TREATMENT OF CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN PATIENTS FROM 6 MONTHS OF AGE AND OLDER
200MG DIFICID CUBIST PHARMS LLC N201699 May 27, 2011 RX TABLET ORAL 8859510 July 31, 2027 TREATMENT OF MICROBIAL INFECTIONS
40MG/ML DIFICID CUBIST PHARMS LLC N213138 Jan. 24, 2020 RX FOR SUSPENSION ORAL 8859510 July 31, 2027 TREATMENT OF CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN PATIENTS FROM 6 MONTHS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
200MG DIFICID CUBIST PHARMS LLC N201699 May 27, 2011 RX TABLET ORAL Jan. 24, 2023 NEW PATIENT POPULATION
40MG/ML DIFICID CUBIST PHARMS LLC N213138 Jan. 24, 2020 RX FOR SUSPENSION ORAL Jan. 24, 2023 NEW PRODUCT
200MG DIFICID CUBIST PHARMS LLC N201699 May 27, 2011 RX TABLET ORAL July 24, 2023 PEDIATRIC EXCLUSIVITY
40MG/ML DIFICID CUBIST PHARMS LLC N213138 Jan. 24, 2020 RX FOR SUSPENSION ORAL July 24, 2023 PEDIATRIC EXCLUSIVITY
200MG DIFICID CUBIST PHARMS LLC N201699 May 27, 2011 RX TABLET ORAL Jan. 24, 2027 PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER FOR THE TREATMENT OF C. DIFFICILE-ASSOCIATED DIARRHEA (CDAD)
40MG/ML DIFICID CUBIST PHARMS LLC N213138 Jan. 24, 2020 RX FOR SUSPENSION ORAL Jan. 24, 2027 PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER FOR THE TREATMENT OF C. DIFFICILE-ASSOCIATED DIARRHEA (CDAD)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA-directed RNA polymerase Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4030846 VUID
N0000182832 NUI
D09394 KEGG_DRUG
4030846 VANDF
CHEBI:68590 CHEBI
FI8 PDB_CHEM_ID
CHEMBL1255800 ChEMBL_ID
CHEMBL445546 ChEMBL_ID
10909 IUPHAR_LIGAND_ID
9038 INN_ID
DB08874 DRUGBANK_ID
Z5N076G8YQ UNII
1111103 RXNORM
181510 MMSL
27891 MMSL
d07778 MMSL
013814 NDDF
703664004 SNOMEDCT_US
703665003 SNOMEDCT_US
C0065023 UMLSCUI
D000077732 MESH_DESCRIPTOR_UI
10034073 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dificid HUMAN PRESCRIPTION DRUG LABEL 1 52015-080 TABLET, FILM COATED 200 mg ORAL NDA 30 sections
Dificid HUMAN PRESCRIPTION DRUG LABEL 1 52015-080 TABLET, FILM COATED 200 mg ORAL NDA 30 sections
DIFICID HUMAN PRESCRIPTION DRUG LABEL 1 52015-700 GRANULE, FOR SUSPENSION 200 mg ORAL NDA 30 sections
DIFICID HUMAN PRESCRIPTION DRUG LABEL 1 52015-700 GRANULE, FOR SUSPENSION 200 mg ORAL NDA 30 sections